Search by drug, manufacturer, or indication

Displaying 801 - 810 of 1165

Erleada (apalutamide)

Status:

Concluded with an LOI

Manufacturer:

Janssen Inc.

Indication:

Non-metastatic Castration-resistant prostate cancer

Last updated July 9, 2019

Mvasi (bevacizumab)

Status:

Concluded with an LOI

Manufacturer:

Amgen Canada Inc.

Indication:

Metastatic Colorectal Cancer / Non-Small Cell Lung Cancer

Last updated July 8, 2019

Fycompa (perampanel)

Status:

Concluded with an LOI

Manufacturer:

Eisai Limited

Indication:

Epilepsy, primary generalized tonic-clonic seizures

Last updated July 2, 2019

Spinraza (nusinersen)

Status:

Concluded with an LOI

Manufacturer:

Biogen Canada Inc.

Indication:

Spinal Muscular Atrophy

Last updated June 26, 2019

Xolair (omalizumab)

Status:

Concluded without agreement

Manufacturer:

Novartis Pharmaceuticals Canada Inc.

Indication:

Severe Persistent Asthma

Last updated June 25, 2019

Ella (ulipristal acetate)

Status:

Concluded with an LOI

Manufacturer:

Allergan Inc.

Indication:

Conception Control

Last updated June 21, 2019

Tremfya (guselkumab)

Status:

Concluded without agreement

Manufacturer:

Janssen Inc.

Indication:

Psoriasis, moderate to severe plaque

Last updated June 21, 2019

Brilinta (ticagrelor)

Status:

Concluded with an LOI

Manufacturer:

AstraZeneca Canada Inc.

Indication:

Secondary Prevention of Atherothrombotic Events

Last updated June 19, 2019

Jublia (efinaconazole)

Status:

Negotiations were not pursued

Manufacturer:

Bausch Health, Canada Inc.

Indication:

Onychomycosis

Last updated June 19, 2019

Biktarvy (bictegravir/emtricitabine/tenofovir alafenamide)

Status:

Concluded with an LOI

Manufacturer:

Gilead Sciences Canada Inc.

Indication:

HIV-1 Infection

Last updated June 14, 2019